Sionna Therapeutics Q1 net loss $26.8M; Phase 2a enrollment completed for SION-719

Sionna Therapeutics, Inc.

2026-Q1 EPS reported -$0.60

Net loss of $26.8M for Q1 2026, compared to $16.5M in Q1 2025.
R&D expenses $19.0M (vs. $13.7M), G&A expenses $10.6M (vs. $6.0M) year-over-year.
Cash and equivalents $289.9M; expected to fund operations into 2028.
Phase 2a POC trial of SION-719 fully enrolled; topline data expected summer 2026.
Phase 1 dual-combination trial of SION-451 also on track for topline data summer 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Sionna Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.8 million.

Period: the first quarter ended March 31, 2026
Net income: Net loss was $26.8 million
Result: reported results

Exact text from the filing

Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Sionna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.